Lupin launches Penicillamine Tablets

Lupin launches Penicillamine Tablets

Mar 02, 2021 03:03 IST capital market

Lupin (Lupin) today announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen? Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilsons disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.

Penicillamine Tablets USP, 250 mg (RLD: Depen?) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).

Powered by Capital Market - Live News

Related Story

Explore Important Blogs